Advertisement
Advertisement

CASI

CASI logo

CASI Pharmaceuticals, Inc. Ordinary Shares

0.95
USD
Sponsored
0.00
-0.05%
Feb 05, 12:23 UTC -5
Closed
exchange

Pre-Market

0.95

0.00
+0.32%

CASI Earnings Reports

Positive Surprise Ratio

CASI beat 19 of 36 last estimates.

53%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/
-46.27%
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

CASI Pharmaceuticals, Inc. Ordinary Shares earnings per share and revenue

On Nov 14, 2025, CASI reported earnings of -0.67 USD per share (EPS) for Q3 25, missing the estimate of -0.40 USD, resulting in a -64.22% surprise. Revenue reached 3.08 million, compared to an expected --, with a 0.00% difference. The market reacted with a -5.56% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an decrease of -46.27% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, CASI Pharmaceuticals, Inc. Ordinary Shares reported EPS of -$0.67, missing estimates by -64.22%, and revenue of $3.08M, 0% as expectations.
The stock price moved down -5.56%, changed from $1.26 before the earnings release to $1.19 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 3 analysts, CASI Pharmaceuticals, Inc. Ordinary Shares is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement